February 10, 2021
Via: Genetic Engineering and Biotechnology NewsThe FDA last night granted Emergency Use Authorization (EUA) for a 700 mg dose of bamlanivimab (LY-CoV555) in combination with a 1400 mg dose of a second Lilly antibody candidate, etesevimab (LY-CoV016), for the treatment of mild to moderate COVID-19 […]
September 19, 2023
September 14, 2023
September 7, 2023
September 5, 2023
September 20, 2023
September 1, 2023
September 14, 2023
August 30, 2023